Antifungal prophylaxis in bone marrow transplantation

Area of Science:

• Medical Mycology
• Hematology
• Transplant Medicine

Background:

• Deep fungal infections are a major cause of mortality in bone marrow transplant (BMT) recipients.
• Prolonged neutropenia is the primary risk factor for invasive fungal disease in this population.
• Candida and Aspergillus species are the most frequent pathogens encountered.

Purpose of the Study:

• To review the efficacy of current antifungal prophylaxis strategies in BMT recipients.
• To discuss emerging antifungal agents and novel measures for preventing fungal infections in BMT patients.

Main Methods:

• Review of existing literature on antifungal prophylaxis in bone marrow transplantation.
• Analysis of the limitations of current prophylactic agents like oral polyenes (nystatin, amphotericin B) and ketoconazole.
• Discussion of the potential of new antifungal agents and preventive strategies.

Main Results:

• Oral polyene prophylaxis has yielded disappointing results in preventing deep fungal infections.
• Systemic amphotericin B, while effective for treatment, is too toxic for prophylaxis.
• Ketoconazole has limitations due to contraindications with cyclosporine and adverse reactions at effective doses.

Conclusions:

• Existing antifungal prophylaxis regimens for BMT recipients are inadequate.
• There is a critical need for improved and safer antifungal strategies to prevent invasive fungal infections.
• Further research into novel antifungal agents and preventive measures is essential for improving outcomes in BMT patients.